Últimas noticias sobre IGC Pharma (AMEX:IGC) Bolsa

IGC PHARMA INC

IGC Pharma

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Pre-Market Outlook

PRGS

QMCO

VERO

XCUR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: PRGS, XCUR, QMCO, VERO e IGC.

5 acciones en el foco en este premercado USA: PRGS, XCUR, QMCO, VERO e IGC

5 acciones en el foco este lunes: PRGS, XCUR, QMCO, VERO e IGC

IGC Pharma Inc

TCW Corporate Bond ETF

INTEGRATED CYBR SOLUTIONS by INTEGRATED CYBER SOLUTIONS INC.

Integrated Cyber Solutions Inc

<a href="https://www.marijuanamoment.net/congressional-committee-moves-to-block-marijuana-rescheduling/">https://www.marijuanamoment.net/congressional-committee-moves-to-block-marijuana-rescheduling/</a>

News

General

AKAN

CRON

GRWG

IMCC

MSOS

SNDL

TLRY

'Congressional Committee Moves To Block Marijuana Rescheduling'- Marijuana Moment

WIIM

IGC Pharma shares are trading higher after the company announced its MINT-AD AI platform to predict Alzheimer's risk.

- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics -
POTOMAC, MD / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 10, 2025 / IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the development of MINT-AD, Multimodal Interpretable Transformer for Alzheimer's, the Company's proprietary AI-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear.
MINT-AD leverages diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories. The platform is being designed for integration into physician workflows to help improve early detection, care personalization and clinical trial enrolment.
IGC expects to launch a beta version of MINT-AD in Fiscal 2026 for pilot evaluation in collaboration with academic and clinical partners. Planned use cases for the platform include integration into electronic health records (EHR) or web-based tools for diagnostic support, enhancing patient stratification, including for our clinical trials, and enabling scalable cognitive assessments in resource-limited settings.

IGC Pharma Develops MINT-AD, Proprietary AI-Powered Diagnostic Platform To Identify High Risk Cognitive Decline Years Before Symptoms Appear

<a href="https://www.marijuanamoment.net/california-senators-approve-bill-to-pause-newly-enacted-marijuana-tax-hike-for-five-years/" title="https://www.marijuanamoment.net/california-senators-approve-bill-to-pause-newly-enacted-marijuana-tax-hike-for-five-years/">https://www.marijuanamoment.net/california-senators-approve-bill-to-pause-newly-enacted-marijuana-tax-hike-for-five-years/</a>

Macro Economic Events

Politics

Global

Economics

LFLY

'California Senators Approve Bill To Pause Newly Enacted Marijuana Tax Hike For Five Years' - Marijuana Moment

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 45.7% to $0.78 during Thursday's pre-market session. The market value of their outstanding shares is at $32.9 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 22.62% to $1.68. The market value of their outstanding shares is at $49.9 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock rose 21.91% to $0.45. The market value of their outstanding shares is at $29.1 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock moved upwards by 17.97% to $5.12. The market value of their outstanding shares is at $562.1 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) stock rose 16.94% to $15.41. The company's market cap stands at $1.0 billion. The company's, Q2 earnings came out yesterday. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares moved upwards by 16.47% to $6.08. The market value of their outstanding shares is at $135.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares decreased by 31.0% to $2.03 during Thursday's pre-market session. The company's market cap stands at $467.4 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares fell 26.91% to $2.88. The market value of their outstanding shares is at $10.1 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) stock decreased by 20.37% to $33.0. The company's market cap stands at $3.9 billion. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares declined by 18.79% to $2.94. The market value of their outstanding shares is at $68.0 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock declined by 18.37% to $0.36. The market value of their outstanding shares is at $27.4 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 16.6% to $1.21. The market value of their outstanding shares is at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEMD

BMGL

CELZ

CGTX

KLTO

LIMN

MREO

NRIX

PASG

PROK

RARE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) rose sharply in today's pre-market trading following a WSJ report <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46332395/wk-kellogg-stock-pops-50-on-potential-3-billion-acquisition">suggesting Ferrero is nearing a deal to acquire the company.</a>
Family-owned Italian candy company Ferrero is closing in on a deal to acquire cereal maker WK Kellogg for roughly $3 billion, according to a Wall Street Journal report. People familiar with the matter reportedly said a deal could be completed as soon as this week.
WK Kellogg shares jumped 50.2% to $26.31 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Steakholder Foods Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKH#NASDAQ">STKH</a>) surged 137.6% to $4.16 in pre-market trading.</li>
<li>GIBO Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) climbed 51.4% to $0.0512 in pre-market trading after dipping 18% on Wednesday.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) rose 51.1% to $20.00 in pre-market trading as the company posted better-than-expected second-quarter results.</li>
<li>IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) jumped 51.1% to $0.5550 in pre-market trading after gaining 15% on Wednesday. IGC Pharma has been making significant strides in its field. In June, the company highlighted its fiscal year 2025 with clinical progress and Alzheimer's drug development advances. This included the presentation of a scientific poster titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," at the 2025 Genetic Toxicology Association Annual Meeting.</li>
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) gained 43.1% to $1.96 in pre-market trading as the company was granted FDA Orphan Drug designation for KLTO-202 for the treatment of amyotrophic lateral sclerosis. </li>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) gained 37.4% to $0.0831 in pre-market trading after gaining 8% on Wednesday.</li>
<li>Pop Culture Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>) gained 29.4% to $0.9000 in pre-market trading. Pop Culture Group, a China-based company focused on developing and hosting hip-hop and other entertainment events, completed a private placement on July 4, 2025.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) gained 15% to $7.01 in pre-market trading after climbing 18% on Wednesday.</li>
<li>ProKidney Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) gained 13.8% to $4.94 in pre-market trading as investors continue to cheer statistically significant and clinically meaningful results from its Phase 2 REGEN-007 trial for rilparencel.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) dipped 36.6% to $1.87 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Creative Medical Technology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares tumbled 25.3% to $2.93 in pre-market trading. Creative Medical Technology has received a notice of allowance for a U.S. patent titled &#8220;Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.&#8221;</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) fell 21.3% to $32.50 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) dipped 17.2% to $3.00 in pre-market trading after gaining 99% on Wednesday.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) fell 15.1% to $8.74 in pre-market trading after the company reported a fourth-quarter adjusted EPS miss.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) fell 13.2% to $1.26 in pre-market trading.</li>
<li>Delixy Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLXY#NASDAQ">DLXY</a>) declined 11.4% to $4.38 in pre-market trading after gaining 24% on Wednesday.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) declined 11% to $1.79 in pre-market trading after dipping 20% on Wednesday.</li>
<li>Scage Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCAG#NASDAQ">SCAG</a>) shares fell 10.5% to $5.89 in pre-market trading after gaining over 56% on Wednesday.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) fell 7.7% to $61.60 in pre-market trading. BitMine Immersion Technologies shares dipped 40% on Wednesday after the company filed for a mixed shelf.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo via Shutterstock

BMNR

CPOP

DLXY

GIBO

NCNA

POET

SCAG

STKH

WOLF

Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket

IGC Pharma Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) witnessed a surge of 69.40%&nbsp; in its stock value during after-hours trading on Wednesday.
What Happened: The stock of IGC Pharma, a company involved in the development of cannabinoid-based therapies for Alzheimer&#8216;s disease, <a href="https://www.google.com/finance/quote/IGC:NYSEAMERICAN?sa=X&amp;ved=2ahUKEwieuY3jmbGOAxWKbmwGHX-XCkcQ3ecFegQINRAb">rose by 69.40%</a> to $0.62. This surge followed the closing price of $0.37 on Wednesday.
See Also: <a href="https://benzinga.com/markets/macro-economic-events/25/07/46312778/scott-bessent-never-made-time-for-japans-trade-negotiator-says-economist-yet-the-us">Scott Bessent Never &#8216;Made Time&#8217; For Japan&#8217;s Trade Negotiator, Says Economist, Yet The US Ally Got Hit With Trump Tariffs — How Should Tokyo Make Sense Of This?</a>
IGC Pharma&#8217;s stock has been on a rollercoaster ride recently. The company&#8217;s stock value had dropped to $0.32 on Tuesday, but it has now rebounded in after-hours trading.
Why It Matters: IGC Pharma has been making significant strides in its field. In June, the company highlighted its fiscal year 2025 with <a href="https://www.benzinga.com/general/biotech/25/06/46167742/igc-pharma-highlights-fiscal-year-2025-with-clinical-progress-and-alzheimers-drug-development-adv">clinical progress and Alzheimer&#8217;s drug development advances</a>. This included the presentation of a scientific poster titled &#8220;Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay,&#8221; at the 2025 <a href="https://investor.igcpharma.com/igc-pharma-presents-genetic-toxicology-safety-data-on-api-in-igc-ad1-at-the-2025-genetic-toxicology-association-meeting/">Genetic Toxicology Association Annual Meeting</a>.
IGC Pharma also <a href="https://www.benzinga.com/insights/earnings/25/06/46140110/insights-ahead-igc-pharmas-quarterly-earnings">beat analyst estimates in its fourth-quarter earnings, reporting an earnings</a> per share of $(0.01) and sales of $330 million, which beat the $305 million estimate. 
Earlier in July, IGC Pharma was also <a href="https://www.benzinga.com/insights/movers/25/07/46332784/12-health-care-stocks-moving-in-wednesdays-after-market-session">listed among the top health care stocks</a> that were moving in the after-market session. This indicates that the company has been attracting investor attention.
Price Action: IGC Pharma shares closed the Wednesday market session 14.02% higher at $0.37 per share- <a href="https://www.benzinga.com/quote/IGC">Benzinga Pro Data</a>
Benzinga Edge Stock Rankings shows IGC stock has Momentum in the 20th percentile. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Additional performance details are available here</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="857" height="163" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09224248/Screenshot-2025-07-10-081230.png" alt="" class="wp-image-979160" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09224248/Screenshot-2025-07-10-081230.png 857w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09224248/Screenshot-2025-07-10-081230-300x57.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09224248/Screenshot-2025-07-10-081230-768x146.png 768w" sizes="(max-width: 857px) 100vw, 857px" /></a></figure>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: kikpokemon on Shutterstock.com
Read Next:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/crypto/25/07/46315623/anthony-scaramucci-once-slammed-dogecoin-other-memecoins-as-distraction-from-the-purity-of-bitcoin-this-is-the-stuff-that-would-aggravate-warren-buffett">Anthony Scaramucci Once Slammed Dogecoin, Other Memecoins As &#8216;Distraction&#8217; From The Purity Of Bitcoin — This Is The Stuff That Would Aggravate Warren Buffett &#8211; Grayscale Bitcoin Mini Trust (BTC) Com</a></li>
</ul>

Biotech

Equities

Health Care

Markets

 IGC

Massive 69.4% Surge for IGC Pharma in After-Hours Trading: Here's Why

<h3>Gainers</h3>
<ul>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares moved upwards by 56.4% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $25.3 million. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) stock moved upwards by 11.03% to $7.95. The market value of their outstanding shares is at $580.9 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares increased by 10.93% to $0.34. The market value of their outstanding shares is at $7.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 9.35% to $5.73. The market value of their outstanding shares is at $163.3 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) stock moved upwards by 7.73% to $14.2. The company's market cap stands at $930.8 million. The company's, Q2 earnings came out today. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 6.95% to $1.23. The company's market cap stands at $2.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares fell 37.7% to $1.83 during Wednesday's after-market session. The market value of their outstanding shares is at $449.9 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) shares fell 27.66% to $29.98. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares declined by 27.33% to $2.86. The company's market cap stands at $6.9 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock declined by 9.95% to $3.26. The market value of their outstanding shares is at $34.1 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 7.59% to $1.34. The market value of their outstanding shares is at $2.3 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares fell 6.73% to $0.55. The company's market cap stands at $90.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTS

PSNL

ZJYL

12 Health Care Stocks Moving In Wednesday's After-Market Session

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders, today unveiled the key achievements and advancements that defined Fiscal Year 2025, ended March 31, 2025. This past year has been nothing short of transformative, marked by significant clinical progress, strategic expansion, and growing recognition for our pioneering approach to Alzheimer's disease.

IGC Pharma Highlights Fiscal Year 2025 With Clinical Progress And Alzheimer's Drug Development Advances

U.S. futures rose on Monday after a record close on Friday. Futures of major benchmark indices were trading higher.
As the <a href="https://www.benzinga.com/25/05/45603240/trump-agrees-to-extend-50-tariffs-on-europe-until-july-9-it-was-my-privilege-to-do-so">July 9 deadline</a> for President Donald Trump&#8216;s reciprocal tariffs comes closer, on Friday, he suggested that the deadline for a U.S.-EU trade deal might not be set in stone.
&#8220;We can do whatever we want,&#8221; he told reporters at the White House. &#8220;We could extend it. We could make it shorter.&#8221; The pause temporarily reduced tariffs to 10%, but they could <a href="https://www.benzinga.com/news/politics/25/06/46156587/trump-says-july-tariff-deadline-not-set-in-stone-we-can-do-whatever-we-want">revert to higher rates</a> unless Trump's executive order from April 9 is amended.
The 10-year Treasury bond yielded 4.25% and the two-year bond was at 3.72%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool&#8217;s</a> projections show markets pricing a 78.8% likelihood of the Federal Reserve keeping the current interest rates unchanged in its July meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.46%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.39%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.62%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.44%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Monday. The SPY was up 0.46% at $617.72, while the QQQ advanced 0.72% to $552.03, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
On Friday, several sectors on the S&amp;P 500 closed with strong gains, led by communication services, consumer discretionary, and industrials stocks. However, energy and healthcare bucked the prevailing market trend, concluding the session in negative territory.
Overall, U.S. stocks settled higher, with the S&amp;P 500 reaching fresh intraday records as investors responded positively to easing global trade tensions and diminishing geopolitical risks, prompting robust buying activity.
Sentiment received a significant boost from President Trump&#8217;s announcement that the U.S. is in the process of finalizing multiple trade agreements.
Trump indicated that four to five deals are either completed or nearing completion ahead of a crucial July 9 deadline. Further bolstering investor confidence, Commerce Secretary Howard Lutnick confirmed a new U.S.-China trade accord, which notably includes tariff reductions and provisions for safeguarding rare earth imports.
Nike Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NK#NYSE">NK</a>) surged by 15% on Friday after the athletic apparel giant reported quarterly earnings that comfortably surpassed Wall Street&#8217;s expectations.
Similarly, Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) saw its shares advance by 6% following a bullish analyst note issued by RedBurn Atlantic, highlighting positive sentiment for the aerospace giant.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.52%</td>
<td>20,273.46</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.52%</td>
<td>6,173.07</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.00%</td>
<td>43,819.27</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.019%</td>
<td>2,172.53</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Following Friday&#8217;s record-breaking rally, Ryan Detrick from Carson Research highlighted historical data and said that the S&amp;P 500 index has never made an all-time high in June since 1950, whereas it has only happened twice in February, excluding this year.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Stocks just made a new all-time high in June. Stocks have never peaked in June. &#x1f9d0; <a href="https://t.co/ItYm8vmOog">pic.twitter.com/ItYm8vmOog</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1938949133832003645?ref_src=twsrc%5Etfw">June 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, he also reiterated that the bull market that began in October 2022 was still active.
He underscored that the S&amp;P 500 has been higher in a post-election year in nine of the past 10 cycles, going back 40 years to 1985.
&#8220;Strength now is normal, it is next year you need to worry about,&#8221; he added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 has been higher in a post-election year nine of the past 10 cycles (going back 40 years to 1985). Strength now is normal, it is next year you need to worry about. <a href="https://t.co/DgnALlx9pe">pic.twitter.com/DgnALlx9pe</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1939518814808363480?ref_src=twsrc%5Etfw">June 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He also highlighted that the market rebounded from April lows to turn positive for the year by the end of July for the first time since 2009.
&#8220;With a day to go until the official midpoint of &#8217;25, the S&amp;P 500 is up 5% YTD,&#8221; he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">With a day to go until the official midpoint of &#39;25, the S&amp;P 500 is up 5% YTD. Only once was it down more YTD at the lows and come all the way back to in the green by the end of June and that was 2009. <a href="https://t.co/uFy3mLJBBJ">pic.twitter.com/uFy3mLJBBJ</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1939522723526381690?ref_src=twsrc%5Etfw">June 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ed Yardeni of Yardeni Research highlighted that tariff delays and AI spending have propelled the S&amp;P 500 index to new highs.
&#8220;Trump started to moderate his stance on tariffs on April 9, and AI companies reiterated their commitment to spend tens of billions of dollars on AI capital investments during April&#8217;s Q1 earnings season. Also boosting the S&amp;P 500 is the record high in S&amp;P 500 forward earnings,&#8221; he stated.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul class="wp-block-list">
<li>On Monday, June&#8217;s Chicago Business Barometer (PMI) will be released by 9:45 a.m. ET.</li>
<li>On Tuesday, June&#8217;s S&amp;P final U.S. manufacturing PMI will be out by 9:45 a.m., and May&#8217;s construction spending and job openings data will be released by 10:00 a.m. ET.</li>
<li>June&#8217;s ISM manufacturing data will be out by 10:00 a.m., whereas auto sales data will also be released on Tuesday.</li>
<li>On Wednesday, June&#8217;s ADP employment data will be out by 8:15 a.m. ET.</li>
<li>On Thursday, initial jobless claims data for the week ended June 28, along with June&#8217;s employment, unemployment, hourly wages, and May&#8217;s trade deficit data, will all be out by 8:30 a.m. ET.</li>
<li>June&#8217;s S&amp;P final U.S. services PMI will be released by 9:45 a.m., whereas ISM services data and May&#8217;s factory orders data will be out by 10:00 a.m. ET.</li>
<li>Markets will be closed on Friday, July 4, for Independence Day.</li>
</ul>
Stocks In Focus:
<ul class="wp-block-list">
<li>Progress Software Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) was up 2.02% in premarket on Monday as analysts expect it to report quarterly earnings of $1.30 per share on revenue of $237.52 million after the closing bell.</li>
<li>Quantum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) rose 1.99% as analysts expect it to report a loss of $1.17 per share on revenue of $65.95 million, after the closing bell.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) jumped 37.61% in premarket after Madryn Asset Management increased its stake in the company to 85.5%.</li>
<li>IGC Pharma Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) gained 3.46% in premarket after reporting a quarterly loss of 1 cent per share, versus market estimates of a loss of 2 cents per share. The company reported quarterly sales of $330,000, which beat the analyst consensus estimate of $305,000.</li>
<li>Klotho Neurosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) surged 29.26% in premarket after announcing progress in manufacturing its investigational ALS gene therapy. The therapy utilizes a unique RNA splice variant of the human alpha-Klotho gene, licensed from the Autonomous University of Barcelona.</li>
<li>Globavend Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) climbed 15.11% after partnering with global online beauty retailer Strawberrynet to target Australia&#8217;s $8.7 billion cosmetics market, aiming to boost premium beauty product accessibility and expand Globavend&#8217;s e-commerce logistics.</li>
<li>Perfect Moment Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#NYSE">PMNT</a>) zoomed 16.89% after announcing that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company.</li>
<li>Genius Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) advanced 13.71% after announcing its Board&#8217;s plan to distribute proceeds from any future legal victories equally between shareholders and the purchase of Bitcoin for its treasury.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.03% to hover around $65.50 per barrel.
Gold Spot US Dollar rose 0.37% to hover around $3,286.47 per ounce. Its last record high stood at $3,500.33 per ounce. The U.S. Dollar Index spot was lower by 0.21% at the 97.1950 level.
Asian markets ended higher on Monday, except Hong Kong's Hang Seng and India's S&amp;P BSE Sensex indices. Japan's Nikkei 225, Australia's ASX 200, China&#8217;s CSI 300, and South Korea's Kospi indices rose. European markets were lower in early trade.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46162886/us-housing-market-is-not-just-broken-its-rigged-says-craig-shapiro-as-mamdani-vows-to-build-200000-publicly-subsidized-homes-freeze-rent-in-nyc">US Housing Market Is &#8216;Not Just Broken, It&#8217;s Rigged,&#8217; Says Craig Shapiro As Mamdani Vows To Build 200,000 Publicly Subsidized Homes, Freeze Rent In NYC</a></li>
</ul>
Photo courtesy: godongphoto / Shutterstock.com

PMNT

US Stocks Likely To Open Higher, Continuing Record-Setting Advances: June Has Never Seen An All-Time High Since 1950, Highlights Expert

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Wall Street expects Progress Software Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) to report quarterly earnings at $1.30 per share on revenue of $237.52 million after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Progress Software shares gained 0.4% to $64.00 in after-hours trading.</li>
<li>Exicure Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) posted earnings of 49 cents per share, versus a year-ago loss of 48 cents per share. Exicure shares gained 2.6% to $6.04 in the after-hours trading session.</li>
<li>Analysts are expecting Quantum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) to post a loss at $1.17 per share on revenue of $65.95 million for the latest quarter. The company will release earnings after the markets close. Quantum shares rose 0.1% to $9.05 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose sharply in after-hours trading after Madryn Asset Management increased its stake in the company to 85.5%. Venus Concept shares jumped 43.6% to $3.13 in the after-hours trading session.</li>
<li>IGC Pharma, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) reported a quarterly loss of 1 cent per share, versus market estimates of a loss of 2 cents per share. The company reported quarterly sales of $330,000, which beat the analyst consensus estimate of $305,000. IGC Pharma shares fell 0.3% to close at $0.3090 on Friday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46136470/jim-cramer-just-revealed-1-oil-stock-he-actually-wants-to-own">Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own</a> </li>
</ul>
Photo courtesy: mariakray / Shutterstock.com

Progress Software, Exicure And 3 Stocks To Watch Heading Into Monday

IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 75 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $330.000 thousand which beat the analyst consensus estimate of $305.000 thousand by 8.20 percent. This is a 11.86 percent increase over sales of $295.000 thousand the same period last year.

Earnings

Earnings Beats

IGC Pharma Q4 EPS $(0.01) Beats $(0.02) Estimate, Sales $330.000K Beat $305.000K Estimate

IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) is gearing up to announce its quarterly earnings on Monday, 2025-06-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that IGC Pharma will report an earnings per share (EPS) of $-0.02.
IGC Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 3.7% drop in the share price the next day.
Here's a look at IGC Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.04</td>
<td>-0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-4.0%</td>
<td>5.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1751032853_0.png" alt="eps graph" />
<h3>IGC Pharma Share Price Analysis</h3>
Shares of IGC Pharma were trading at $0.31 as of June 26. Over the last 52-week period, shares are down 29.42%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/IGC/earnings">To track all earnings releases for IGC Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: IGC Pharma's Quarterly Earnings

IGC Pharma, Inc. ("IGC", or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) today announced the addition of a new clinical trial site at Tekton Research in Yukon, Oklahoma, for its Phase 2 CALMA study evaluating IGC-AD1 for agitation in Alzheimer's dementia. This expansion into the Oklahoma City metropolitan area underscores IGC's commitment to diversifying its trial population and addressing regional healthcare disparities.
Tekton Research has extensive experience conducting clinical trials in therapeutic areas such as Alzheimer's disease, migraine, vaccines, and others. Dr. David McCoy, a board-certified neurologist in Canadian County and a native Oklahoman, will serve as the principal investigator at the Yukon site. Dr. McCoy plays a key role in his community by providing accessible healthcare and maintaining strong relationships with his patients.

IGC Pharma Adds New Clinical Trial Site At Tekton Research In Yukon, Oklahoma, For Phase 2 CALMA Study Evaluating IGC-AD1 For Agitation In Alzheimer's Dementia

<a href="https://themarijuanaherald.com/2025/06/u-s-congress-house-gop-bill-would-ban-most-hemp-derived-thc-products-nationwide/" title="https://themarijuanaherald.com/2025/06/u-s-congress-house-gop-bill-would-ban-most-hemp-derived-thc-products-nationwide/">https://themarijuanaherald.com/2025/06/u-s-congress-house-gop-bill-would-ban-most-hemp-derived-thc-products-nationwide/</a>

FLGC

MAPS

'U.S. Congress: House GOP Bill Would Ban Most Hemp-Derived THC Products Nationwide' - Marijuana Herald

<a href="https://www.marijuanamoment.net/california-assembly-unanimously-passes-bill-to-delay-marijuana-tax-hike-for-five-years/" title="https://www.marijuanamoment.net/california-assembly-unanimously-passes-bill-to-delay-marijuana-tax-hike-for-five-years/">https://www.marijuanamoment.net/california-assembly-unanimously-passes-bill-to-delay-marijuana-tax-hike-for-five-years/</a>

'PoliticsCalifornia Assembly Unanimously Passes Bill To Delay Marijuana Tax Hike For Five Years' - Marijuana Moment

<a href="https://www.marijuanamoment.net/trump-wants-to-delete-state-medical-marijuana-protections-from-budget-while-continuing-to-block-cannabis-sales-legalization-in-d-c/" title="https://www.marijuanamoment.net/trump-wants-to-delete-state-medical-marijuana-protections-from-budget-while-continuing-to-block-cannabis-sales-legalization-in-d-c/">https://www.marijuanamoment.net/trump-wants-to-delete-state-medical-marijuana-protections-from-budget-while-continuing-to-block-cannabis-sales-legalization-in-d-c/</a>

Legal

'Trump Wants To Delete State Medical Marijuana Protections From Budget While Continuing To Block Cannabis Sales Legalization In D.C.' - Marijuana Moment

<a href="https://www.marijuanamoment.net/senate-committee-approves-trumps-dea-pick-who-has-refused-to-say-if-he-supports-marijuana-rescheduling-proposal-before-agency/" title="https://www.marijuanamoment.net/senate-committee-approves-trumps-dea-pick-who-has-refused-to-say-if-he-supports-marijuana-rescheduling-proposal-before-agency/">https://www.marijuanamoment.net/senate-committee-approves-trumps-dea-pick-who-has-refused-to-say-if-he-supports-marijuana-rescheduling-proposal-before-agency/</a>

'Senate Committee Approves Trump's DEA Pick Who Has Refused To Say If He Supports Marijuana Rescheduling Proposal Before Agency' - Marijuana Moment

IGC Pharma, Inc. ("IGC", or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region.
Approximately 12.5% of Puerto Ricans over the age of 65 have Alzheimer's, a figure notably higher than the roughly 10% prevalence observed in older non-Hispanic white populations in the U.S. This disparity is influenced by factors such as Puerto Rico's rapidly aging demographic and unique genetic predispositions. The heightened prevalence translates into a substantial economic burden, with medical care for dementia in Puerto Rico accounting for over a quarter of total societal healthcare costs, a proportion higher than in the continental U.S.

IGC Pharma Announce Clinical Trial Site At Santa Cruz Behavioral In Puerto Rico For CALMA Phase 2 Clinical Trial, Investigating IGC-AD1 For Agitation In Alzheimer's Disease

<a href="https://x.com/MarijuanaMoment/status/1925220244504621454" title="https://x.com/MarijuanaMoment/status/1925220244504621454">https://x.com/MarijuanaMoment/status/1925220244504621454</a>

"Marijuana Rescheduling Blocked By Opposition 'From Within' DEA, Biden's Drug Czar Says" - Marijuana Moment

Press Releases

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

IGC Pharma Welcomes Strategic Investment from Advisors

Events

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Contracts

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

AN2 Therapeutics

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

Hoth Therapeutics

Hyperion DeFi

Iterum Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

NRX Pharmaceuticals

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

SCYNEXIS

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

VYNE Therapeutics

Alliance Global Partners

Ascendiant Capital

India Globalization Cap

Screenshot 2024-05-08 at 6.04.45 PM

OSUKF

6.7 Million Americans Live With Alzheimer&#39;s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings

Screenshot 2024-03-19 at 5.39.00 PM

IGC Pharma Advances In Alzheimer&#39;s Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1

Comments

IGC Pharma

Noticias

Últimas noticias sobre IGC Pharma (AMEX:IGC) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL